NCT03237390View on ClinicalTrials.gov

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

May 17, 2022

Study Completion Date

May 17, 2022

Conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
Interventions
DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Ribociclib

Given PO

Trial Locations (3)

55905

Mayo Clinic, Rochester

85054

Mayo Clinic Hospital, Phoenix

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03237390 - Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter